Literature DB >> 23179251

Therapeutic immunomodulation using a virus--the potential of inactivated orf virus.

O Weber1, A A Mercer, A Friebe, P Knolle, H-D Volk.   

Abstract

Viruses can manipulate the immune response against them by various strategies to influence immune cells, i.e. by over-activation leading to functional inactivation, bypassing antigen presentation or even suppression of effector functions. Little is known, however, about how these features of immune regulation and modulation could be used for therapeutic purposes. Reasons for this include the complexity of immune regulatory mechanisms under certain disease conditions and the risks that infections with viruses pose to human beings. The orf virus (ORFV), a member of the Parapoxvirus genus of the poxvirus family, is known as a common pathogen in sheep and goats worldwide. The inactivated ORFV, however, has been used as a preventative as well as therapeutic immunomodulator in veterinary medicine in different species. Here, we review the key results obtained in pre-clinical studies or clinical studies in veterinary medicine to characterise the therapeutic potential of inactivated ORFV. Inactivated ORFV has strong effects on cytokine secretion in mice and human immune cells, leading to an auto-regulated loop of initial up-regulation of inflammatory and Th1-related cytokines, followed by Th2-related cytokines that attenuate immunopathology. The therapeutic potential of inactivated ORFV has been recognised in several difficult-to-treat disease areas, such as chronic viral diseases, liver fibrosis or various forms of cancer. Further research will be required in order to evaluate the full beneficial potential of inactivated ORFV for therapeutic immunomodulation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23179251     DOI: 10.1007/s10096-012-1780-x

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   5.103


  66 in total

1.  Orf virus encodes a novel secreted protein inhibitor of granulocyte-macrophage colony-stimulating factor and interleukin-2.

Authors:  D Deane; C J McInnes; A Percival; A Wood; J Thomson; A Lear; J Gilray; S Fleming; A Mercer; D Haig
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  [Experimental detection of the paraspecific effects of purified and inactivated poxviruses].

Authors:  A Mayr; M Büttner; G Wolf; H Meyer; C Czerny
Journal:  Zentralbl Veterinarmed B       Date:  1989-03

3.  Effect of IL-10 on the expression of HSC growth factors in hepatic fibrosis rat.

Authors:  Mei-Na Shi; Wei-Da Zheng; Li-Juan Zhang; Zhi-Xin Chen; Xiao-Zhong Wang
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

Review 4.  Feline gingivitis-stomatitis-pharyngitis.

Authors:  K Diehl; R A Rosychuk
Journal:  Vet Clin North Am Small Anim Pract       Date:  1993-01       Impact factor: 2.093

Review 5.  [Present state of preclinical research on the efficacy and safety of para immunity inducers from poxviruses. A study of the literature].

Authors:  B Mayr; A Mayr
Journal:  Tierarztl Prax       Date:  1995-12

6.  Highly attenuated poxviruses induce functional priming of neutrophils in vitro.

Authors:  R Förster; G Wolf; A Mayr
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

7.  A nuclear inhibitor of NF-kappaB encoded by a poxvirus.

Authors:  D G Diel; S Luo; G Delhon; Y Peng; E F Flores; D L Rock
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

8.  A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases.

Authors:  M Meyer; M Clauss; A Lepple-Wienhues; J Waltenberger; H G Augustin; M Ziche; C Lanz; M Büttner; H J Rziha; C Dehio
Journal:  EMBO J       Date:  1999-01-15       Impact factor: 11.598

Review 9.  Ovine diseases. Orf.

Authors:  D M Haig; A A Mercer
Journal:  Vet Res       Date:  1998 May-Aug       Impact factor: 3.683

10.  Orf virus encodes a homolog of the vaccinia virus interferon-resistance gene E3L.

Authors:  C J McInnes; A R Wood; A A Mercer
Journal:  Virus Genes       Date:  1998       Impact factor: 2.198

View more
  12 in total

Review 1.  Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B.

Authors:  Aleksei Suslov; Stefan Wieland; Stephan Menne
Journal:  Curr Opin Virol       Date:  2018-02-20       Impact factor: 7.090

2.  Orf virus (ORFV) ANK-1 protein mitochondrial localization is mediated by ankyrin repeat motifs.

Authors:  Krzysztof Lacek; Berthilde Bauer; Krystyna Bieńkowska-Szewczyk; Hanns-Joachim Rziha
Journal:  Virus Genes       Date:  2014-04-18       Impact factor: 2.332

3.  AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B.

Authors:  Daniela Paulsen; Olaf Weber; Helga Ruebsamen-Schaeff; Bud C Tennant; Stephan Menne
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

4.  Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization.

Authors:  Daniel W Sharp; Edmund C Lattime
Journal:  Biomedicines       Date:  2016-08-12

5.  Transcriptomic profiles of human foreskin fibroblast cells in response to orf virus.

Authors:  Daxiang Chen; Mingjian Long; Bin Xiao; Yufeng Xiong; Huiqin Chen; Yu Chen; Zhenzhan Kuang; Ming Li; Yingsong Wu; Daniel L Rock; Daoyuan Gong; Yong Wang; Haijian He; Fang Liu; Shuhong Luo; Wenbo Hao
Journal:  Oncotarget       Date:  2017-04-25

6.  Treatment with the Immunomodulator AIC649 in Combination with Entecavir Produces Antiviral Efficacy in the Woodchuck Model of Chronic Hepatitis B.

Authors:  Kyle E Korolowicz; Manasa Suresh; Bin Li; Xu Huang; Changsuek Yon; Xuebing Leng; Bhaskar V Kallakury; Robin D Tucker; Stephan Menne
Journal:  Viruses       Date:  2021-04-09       Impact factor: 5.048

7.  Inactivated ORF virus shows antifibrotic activity and inhibits human hepatitis B virus (HBV) and hepatitis C virus (HCV) replication in preclinical models.

Authors:  Daniela Paulsen; Andreas Urban; Andreas Knorr; Claudia Hirth-Dietrich; Angela Siegling; Hans-Dieter Volk; Andrew A Mercer; Andreas Limmer; Beatrix Schumak; Percy Knolle; Helga Ruebsamen-Schaeff; Olaf Weber
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

8.  New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus.

Authors:  Jörg Rohde; Ralf Amann; Hanns-Joachim Rziha
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

9.  Inactivated Parapoxvirus ovis induces a transient increase in the expression of proinflammatory, Th1-related, and autoregulatory cytokines in mice.

Authors:  D Anziliero; R Weiblen; L C Kreutz; F Spilki; E F Flores
Journal:  Braz J Med Biol Res       Date:  2014-01-17       Impact factor: 2.590

10.  Genomic Characterization of Orf Virus Strain D1701-V (Parapoxvirus) and Development of Novel Sites for Multiple Transgene Expression.

Authors:  Hanns-Joachim Rziha; Mathias Büttner; Melanie Müller; Ferdinand Salomon; Alena Reguzova; Dominic Laible; Ralf Amann
Journal:  Viruses       Date:  2019-01-30       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.